While it is known that cancer cell interactions with vascular endothelial cells (ECs) drive metastatic cancer cell extravasation from blood vessels into secondary tumor sites, the mechanisms of action are still poorly understood. Here, we tested the hypothesis that neuraminidase-induced degradation of EC surface glycocalyx (GCX), particularly the sialic acid (SA) residue components of the GCX, will substantially increase metastatic cancer cell attachment to ECs. To our knowledge, our study is the first to isolate the role of GCX SA residues in cancer cell attachment to the endothelium, which were found to be differentially affected by the presence of neuraminidase and to indeed regulate metastatic cancer cell homing to ECs. We hope that this work will eventually translate to identification of EC GCX-based cancer markers that can be therapeutically targeted to hinder the progression of metastasis.
environment (Figure 1a
. [7] [8] [9] [10] [11] [12] The EC GCX is composed of a variety of sugar chains, glycoproteins, and soluble proteins. For example, the GCX includes core proteins on which heparan sulfate (HS), chondroitin sulfate (CS), and hyaluronic acid (HA) glycosaminoglycan sugar chains are attached. 9 HS is the most abundant GCX component.
The core proteins are also attached to sialic acid (SA) on their terminal ends. 13 Degradation of these key components of GCX is associated with certain conditions and diseases including inflammation, sepsis, atherosclerosis, and cancer. [14] [15] [16] [17] [18] To date, only a few cell mechanism studies have explored how HS, CS, HA, and SA regulate homing of cells, particularly white blood cells and cancer cells, from vessel circulation to the endothelium surface. 6, [19] [20] [21] [22] [23] [24] [25] [26] [27] Selected reports are summarized in Table 1 , which shows that the majority of investigations have been performed in the context of white blood cells and inflammation, [19] [20] [21] [22] 24, [28] [29] [30] and more work is required in the cancer milieu to address metastasis. 6, [25] [26] [27] The white blood cell studies inform our understanding of GCX-mediated EC adhesiveness to cancer cells, because cancer cells utilize inflammation mechanisms to metastasize 18, [31] [32] [33] and inflammatory agonists are known to cause endothelial GCX shedding 34 that can expose endothelium to circulating cell adhesion. With respect to GCX componentspecific shedding, research has largely been focused on studying the role of HS loss in cancer and inflammatory cell adhesion, due to its abundance in the GCX (Table 1) . 6, 20, 22, 23, 35 Some work has gone into investigating how losses in HS and CS, combined, contribute to endothelium adhesiveness. 21, 24 Experiments conducted to isolate and elucidate the mechanisms of EC adhesiveness involving HA are rare, 26 and studies isolating SA-mediated EC adhesiveness have not been performed at all, to our knowledge (Table 1) .
Relevant to endothelium adhesiveness to cells in the blood vessels, SA is of particular interest because it is a major contributor to cellular and molecular recognition. [36] [37] [38] This is due to the diversity of SA residues, which are differentiated through post-transcriptional sialytransferase activity. 22, 27, 28 On ECs, several SA residues are expressed, but the most notable include the /-2,6-linked, /-2,3-linked, and /-2,8-linked SA residues. These residues recognize and interact with cells and molecules through lectins, which are proteins that recognize and bind to SA and other sugars. 37 In addition, SA residues are uniquely composed of amino acids and carboxyl groups that make them negatively charged, further enhancing SA's ability to facilitate recognition and binding or repulsion to other cells or molecules. SA's terminal location, diversity, composition, and charge, taken together, are important determinants of EC GCX-mediated endothelial barrier function. Yet, while the role of SA in the cancer cell GCX has been extensively studied and found as a marker of oncogenesis and tumor survival, [39] [40] [41] the role of SA in the endothelial GCX during oncogenesis has yet to be studied.
Another reason for our interest in SA stems from reports that the SA-degrading enzyme, neuraminidase (Neur), 42 is strongly associated with cancer metastasis and other pathologies. Specifically, Neur upregulation has been reported in hepatocellular carcinoma and ovarian cancer, and Neur has been noted to be an oncogene that enhances proliferation and migration of metastatic cancer cells. 35, 43 Based on these reports, it is surprising that not much effort has been made to elucidate the impact of excessive Neur on ECs, which are likely to respond by shedding their SA residues, leading to cancer cell access to the endothelium.
F I G U R E 1 (a) Drawing shows endothelium with intact GCX. As metastatic cancer cells move with blood flow, the healthy GCX blocks the adhesion ligands on the cancer cells from attaching to the adhesion receptors on the endothelium lining of the blood vessel wall. We hypothesize that cancer cell attachment to the endothelium is caused by endothelial GCX degradation. (b, c) These drawings illustrate the conclusions of the findings reported herein. Our observations provide evidence that the systemic increase in Neur (b), which coincides with metastatic cancer conditions, degrades the GCX as a whole and as applied to its/-2,6-linked and /-2,3-linked SA residues (c). This GCX degradation leads to increased cancer cell attachment to ECs, and we speculate that this is mediated by exposure of adhesion receptors on the endothelium which become accessible to adhesion ligands on cancer cells (c In the present study, we aimed to test the hypothesis that Neurinduced degradation of EC GCX, particularly the shedding of SA residues, will result in substantial increase in metastatic cancer cell attachment to the endothelium. To test our hypothesis, we first characterized the expression of the GCX, both generally and with a specific focus on a SA residue. We then investigated the effects of Neur on the GCX.
Last, we investigated the effect of GCX degradation on the attachment of metastatic cancer cells to the endothelium. Our findings indicate that SA residues are differentially affected by the presence of Neur and confirm that GCX degradation indeed leads to increased cancer cell attachment to the endothelium. We anticipate that this body of work will extend our knowledge on the role played by GCX, specifically regarding SAs, in regulating movement of metastatic cancer cells from blood vessels to secondary metastatic sites. This will lead to future research to identify innovative GCX-based markers that can be therapeutically targeted to hinder the progression of cancer metastasis.
| MATERIALS AND METHODS

| Endothelial cell culture
GCX-rich rat fat pad endothelial cells (RFPECs) 44 
| Neur enzyme degradation of the endothelial GCX
To model endothelial GCX degradation, RFPECs were cultured for 2 hr in DMEM/1% PS/10% FBS with 0 (untreated control), 15, 135, 1,215, or 3,645 mU/mL of the SA-degrading enzyme, Neur from Clostridium perfringens (Sigma). 45 After the 2-hr period ended, RFPECs were cultured in enzyme-free culture media before further experimentation.
| Endothelial GCX lectin staining, confocal microscopy, and image analysis
Fluorescent staining was performed to assess GCX expression on untreated or Neur-treated RFPECs. This was achieved using lectins,
proteins that recognize and bind to sugars. 37 After the Neur treatment period, RFPEC monolayers, fixed with 2% paraformaldehyde/0.1% glutaraldehyde, were incubated with various GCX labeling-lectins ( RFPECs were then imaged using a Zeiss Confocal Laser Scanning
Microscope 700 with a ×63 magnification objective (oil). Analysis was performed using NIH ImageJ software. For detailed methods, see SI Materials and Methods and our previously published work. 
| Statistics
Please refer to SI Materials and Methods for details. In brief, data sets were reduced to means ± SEM. When two treatments were compared, Student's t tests were used to determine statistical significances between groups. For multiple comparisons, one-way ANOVA analyses and Tukey post hoc tests were used to determine statistical signifi-
cance. An alpha value of p < .05 was used for both t tests and ANOVA.
| RESULTS AND DISCUSSION
The endothelial GCX plays a significant role as a barrier between the endothelium and circulating cells present in the blood stream, including cancer cells. 6, [19] [20] [21] [22] [23] [24] [25] [26] [27] The importance of the endothelial GCX in enabling EC adhesiveness to cancer and other types of circulating cells, primarily when its HS component is shed or in the presence of heparinase enzyme that specifically degrades HS, has been well established (Table 1) . 6, [19] [20] [21] [22] [23] [24] [25] 27 Regulation of EC adhesiveness by endothelial GCX components such as CS and HA has also been demonstrated (Table 1) . 6, [20] [21] [22] [23] [24] [25] [26] Another important endothelial GCX component, namely SA, its residues, and its degrading enzyme, Neur, remains understudied in the context of EC adhesion to circulating cancer cells (Table 1 ). The present study aimed to fill this gap, by studying the impact of Neurinduced degradation of EC GCX, particularly the SA component, on metastatic cancer cell attachment to the endothelium.
| Neur elevation in the EC environment destabilizes wheat germ agglutinin-labeled GCX
RFPECs were selected as an appropriate cell model for this study because of their ability to produce robust GCX even in static conditions, while other cell culture models require shear stress to stimulate the synthesis of GCX. 44 Upon the initial inspection of RFPECs treated with Neur, we observed that RFPEC monolayers exposed to Neur had preserved morphology (compared to untreated samples) indicating that only the GCX would be affected by the presence of the enzyme and not the underlying endothelium (Figure 2a-e) .
To determine the effects of Neur on GCX integrity, RFPECs were first labeled with wheat germ agglutinin (WGA) (Figure 2f-i) . WGA is reported to delineate the overall GCX structure better than other lectins, 47 and binds to a number of SA residues along with a few other GCX components (Table 2) . We discovered that at baseline conditions (i.e., in the absence of Neur), WGA-labeled GCX covered 73.8 ± 7.4%
of RFPEC monolayers (Figure 2f ), represented by a normalized value of 1.00 ± 0.07 (Figures 3a and 4a) . WGA-labeled GCX thickness was 1.46 ± 0.02 μm, a normalized value of 1.00 ± 0.02 (Figures 3b and   4b ). Previously, Reitsma et al reported a WGA-labeled GCX layer to The coverage and thickness of the WGA-labeled GCX in our study was less, which could be attributed to differential GCX expression in varying vascular tissue beds. 7, 50, 51 Additionally, our in vitro GCX is expected to be thinner than that found in vivo due to the absence of bovine serum albumin in the experimental media and also the collapse of the GCX that occurs outside of the in vivo environment. 5b ). Clearly, as Neur concentration increases, the underlying endothelium membrane is exposed.
| Neur increase degrades /-2,3-linked residue of GCX SA
33.7 ± 2.4% of the untreated RFPEC surface was covered by /-2,3-linked SA. This result was normalized to 1.00 ± 0.08 (Figure 6a ).
The corresponding thickness was 1.83 ± 0.06 μm, also normalized to a value of 1.0 ± 0.08 (Figure 6b ). Taking these results into consideration clarifies that /-2,3-linked SA residue provided less baseline coverage than WGA-labeled GCX and higher baseline RFPEC coverage than /-2,6-linked SA residue (Figure 2f-t) . In addition, comparing /-2,3-linked SA residue to /-2,6-linked SA residue, it is worth mentioning that /-2,3-linked SA residue expression is less patchy and discontinuous than /-2,6-linked SA residue (Figure 2k-t) . These observations reveal differential expression of these SA residues and may also indicate that different ECs could have different presentations of these SA residues. 55 In fact, Cioffi et al reported that Figures 3a and 6a) . Figure 3 is shown again, for comparison to expression of SNA-labeled /-2,6-linked SA residue. At 0 mU/mL, N = 9; at 15 mU/mL, N = 8; at 135 mU/mL, N = 8; at 1,215 mU/mL, N = 9; and at 3,645 mU/mL, N = 9, and representative images used for this data are shown in Figure 2u -y. EC, endothelial cell; SA, sialic acid; SNA, Sambucus nigra (elderberry bark) lectin
The extent of EC coverage by SA and the thickness of SA, as assessed by quantifying MAL II-labeled /-2,3-linked SA residue, are compared to the number of cancer cells that attach to endothelium. Results are normalized to 0 mU/mL baseline conditions, which are indicated by the dashed lines (---). Significance is denoted as *p < .05, **p < .01, and ****p < .0001. The corresponding normalized thicknesses of /-2,3-linked SA after enzyme treatment were decreased to 0.9 ± 0.2, 019 ± 0.09, 0.2 ± 0.1, and 0.08 ± 0.03, respectively (Figures 3b and 6b ).
| Neur-induced GCX loss leads to increased cancer cell attachment to ECs
After establishing a degradation profile for GCX and its SA components we coincubated Neur treated and nontreated RFPEC monolayers with labeled 4T1 breast cancer cells to determine the effect of Neur on cancer attachment to the endothelium. Before the addition of the enzyme to ECs, there was a baseline attachment of cancer cells to ECs (Figure 2u ), normalized to a value of 1.00 ± 0.22 (Figures 4-6 ). This could be attributed to the barrier created by the terminal positions of sugar chains within the GCX matrix. 56, 57 These GCX structures found on the apical surface of the GCX structure mediate intercellular recognition and binding. 
| CONCLUSIONS
The goal of this study was to clarify how the GCX, specifically the understudied SA component of the GCX, contributes to GCXmediated protection of the endothelium against cancer cell adhesion.
Toward this end, we have confirmed differential expression of WGAlabeled GCX, /-2,6-linked SA, and /-2,3-linked SA on the endothelium. We found that the presence of Neur in the EC environment sheds these components and enables ECs to become adhesive to floating cancer cells (Figure 1b,c) . Graded Neur dosing and systematic GCX degradation revealed that there is a necessary threshold of degradation of both GCX coverage and thickness on ECs at which the attachment of 4T1 breast cancer cells to the endothelium is substantially enhanced in a manner that could promote metastasis.
Further understanding of endothelial GCX mechanisms of cancer metastasis is needed. Ongoing work in our lab includes studies of human EC interaction with human cancer cells. We expect the human cell studies will confirm and build upon the rodent cell results reported herein.
For example, in critical control experiments, we have confirmed that untreated human umbilical vein endothelial cells (HUVEC; Figure 7a) highly express GCX components such as those targeted by WGA Finally, in our human cell studies, under flow conditions, we are also comparing the role of SA to the role of EC surface adhesion molecules (Mensah et al, manuscript in review). In the future, we look forward to interrogating additional GCX components ( Table 1 ). The aim is to eventually clarify how the various GCX components and the adhesion molecules synergistically contribute to cancer cell attachment to the endothelium. Studying the role of the EC GCX as compared to the role of the EC adhesion molecules from a perspective that has a human-context, considers both enzyme and flow conditions, and looks at the multiple GCX components, we will expand upon our pre-existing knowledge of the relationship between endothelial GCX degradation and cancer attachment. Our long-term goal is to apply this knowledge to the development of therapeutic means to prevent the endothelial GCX degradation in a hope of hindering or even preventing cancer metastasis.
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